Overview
LGVN market data
Price History
LGVN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for LGVN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Longeveron Inc. (LGVN)SEC EDGAR · Jul 14, 2026, 9:19 PM
Longeveron Alzheimer’s Therapy Shows Brain Inflammation Benefits, Presents New Alzheimer’s Stem Cell Therapy DataBenzinga · Jul 13, 2026, 11:17 AM
Longeveron Names Marie Washburn as Chief Financial Officer Effective On July 13; Lisa Locklear To Step Down As CFOBenzinga · Jul 6, 2026, 8:10 PM
Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15Benzinga · Jun 18, 2026, 1:30 PM
Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines AgencyBenzinga · Jun 9, 2026, 1:25 PM
Longeveron CFO Lisa Locklear Plans To Step Down, Effective July 10Benzinga · Jun 5, 2026, 8:10 PM
Longeveron Q1 2026 Earnings Call: Complete TranscriptBenzinga · May 13, 2026, 9:09 PM
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K EstimateBenzinga · May 13, 2026, 8:42 PM
Earnings Scheduled For May 13, 2026Benzinga · May 13, 2026, 11:11 AM
Longeveron Phase 2b HLHS Cell Therapy Trial Clears Final Safety Review; Top-Line Results Expected August 2026Benzinga · May 11, 2026, 1:11 PM